轻度哮喘:困境、复杂性及个体化治疗的必要性
轻中度哮喘涵盖广泛的表型与症状负担,占全球哮喘患者多数。轻度哮喘因异质性和影响谱广而难以定义,且可发生严重急性发作。评估应结合症状控制与急性发作风险,指南支持起始抗炎治疗、避免单用缓解药,并采用共享决策与可治疗特质方法。
要点
- 轻度哮喘可发生严重急性发作,不应视为低风险。
- 起始治疗应使用抗炎药物,避免仅用缓解药治疗。
- 采用共享决策与可治疗特质方法优化个体化照护。
核心结论
- 轻度哮喘应被视为可逆、潜在可治愈的疾病,通过减少触发因素和优化照护实现长期缓解。
研究设计与样本
- 本文为综述,总结轻中度哮喘的定义困境、评估方法与治疗原则。
主要发现
- 轻中度哮喘覆盖广泛表型和症状负担,占全球哮喘患者多数。
- 轻度哮喘异质性强、影响谱广,且与严重急性发作相关。
- 评估轻中度哮喘最佳方式是结合症状控制与急性发作风险。
关键数值与推荐
- 指南支持起始抗炎药物治疗,完全避免仅用缓解药治疗轻度哮喘。
临床怎么用
- 采用共享决策与可治疗特质方法,确保整体照护以最大化患者结局。
- 通过减少触发因素和优化照护,使轻度哮喘患者维持长期缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mild and moderate asthma cover a wide range of asthma presentations, phenotypes and symptom burden, and account for the majority of people with asthma worldwide. Mild asthma has been difficult to define because of its heterogeneity and wide spectrum of impact and outcomes, including being associated with severe exacerbations. Assessment of mild-moderate asthma is best made by combining asthma symptom control and exacerbation risk as the principle means by which to determine treatment needs. Incontrovertible evidence and guidelines support treatment initiation with anti-inflammatory medication, completely avoiding reliever-only treatment of mild asthma. Shared decision making with patients and a treatable traits approach will ensure that a holistic approach is taken to maximize patient outcomes. Most importantly, mild asthma should be regarded as a reversible, potentially curable condition, remaining in long-term remission through minimizing triggers and optimizing care.
引用
- Jenkins. Mild asthma: Conundrums, complexities and the need to customize care. Respirology. 2023. PMID: 38143421. doi:10.1111/resp.14646
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。